Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

PACB · Nasdaq · United States · Laboratory Analytical Instruments

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Menlo Park, CA · Fiscal year ends in December · Figures in USD

+ Add to watchlist Compare

In shortPACIFIC BIOSCIENCES OF CALIFORNIA, INC. is loss-making.

Financial health

Weak

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

How is this score calculated? →

Profitability0

Operating marginShare of each sale left after running the business, before interest and tax.	-346.2%	0/100
Net marginShare of each sale left as profit after every cost, interest and tax.	-341.5%	0/100
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	-213.5%	0/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	–	n/a

Weight in the score: 25%

Balance sheet33

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	5.15×	100/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	–	n/a
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	–	n/a
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	-79.65×	0/100
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	-13.42	0/100

Weight in the score: 25%

Cash generation0

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	-71.2%	0/100
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	–	n/a
Years with positive free cash flow (last 5)	0 of 5	0/100

Weight in the score: 20%

Stability8
Profitable years (last 5) 0 of 5 0/100
Years of revenue decline (last 5) 2 of 5 33/100
Revenue growth volatility 38.7% 0/100
Operating margin volatility 82.7% 0/100
Weight in the score: 20%
Growth59
Revenue growth, 3-year average 7.6% 59/100
EPS growth, 3-year average – n/a
Weight in the score: 10%

Profitable years (last 5)	0 of 5	0/100
Years of revenue decline (last 5)	2 of 5	33/100
Revenue growth volatility	38.7%	0/100
Operating margin volatility	82.7%	0/100

Revenue growth, 3-year average	7.6%	59/100
EPS growth, 3-year average	–	n/a

Fiscal year 2025 · change vs prior year

Revenue: $160.0M; ▲ 3.9%
Net income: −$546.4M; ▼ 76.3%
Free cash flow: −$113.9M; ▲ 46.3%
Operating margin: −346.2%; −38.2 pts
Cash & investments: $279.5M; –
Total debt: –; –
Diluted EPS: −$1.82; ▼ 14.5%
Return on equity: −213.5%; –

Trends

Annual figures as reported. Hover a bar or point for the exact value.

5 older years available with the 10-year history. Essential plan, from €8.25/month →

Revenue and net income

RevenueNet income

Margins

Statements

The last 5 fiscal years from the company's annual reports.

USD millions; negative values in parentheses.

Fiscal year	FY21	FY22	FY23	FY24	FY25
Revenue	131	128	201	154	160
Cost of revenue	72	79	148	117	114
Gross profit	59	49	53	37	46
Research & development	113	193	187	135	97
Selling, general & admin	124	161	170	175	141
Operating income	(210)	(307)	(334)	(474)	(554)
Interest expense	13	15	14	13	7
Pre-tax income	(275)	(314)	(318)	(310)	(546)
Income tax	(94)	0	(11)	0.3	0.3
Net income	(181)	(314)	(307)	(310)	(546)
Diluted EPS	−$0.89	−$1.40	−$1.21	−$1.59	−$1.82
Diluted shares (millions)	204	225	254	288	300

5 older years available with the 10-year history. Essential plan, from €8.25/month →

Risk checks

Altman Z'' score

−13.42 Distress zone

Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.

Piotroski F-score

4/9

Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.

Positive net income: failed
Positive operating cash flow: failed
Return on assets improved: failed
Cash flow exceeds net income: passed
Long-term debt ratio fell: passed
Current ratio improved: failed
No share dilution: failed
Gross margin improved: passed
Asset turnover improved: passed

Sources

10-QPeriod ending Jun 30, 2026Filed Aug 6, 2026Open the report ↗
10-QPeriod ending Mar 31, 2026Filed May 8, 2026Open the report ↗
10-KPeriod ending Dec 31, 2025Filed Feb 25, 2026Open the report ↗
10-QPeriod ending Sep 30, 2025Filed Nov 6, 2025Open the report ↗
10-QPeriod ending Jun 30, 2025Filed Aug 7, 2025Open the report ↗
10-QPeriod ending Mar 31, 2025Filed May 12, 2025Open the report ↗
10-KPeriod ending Dec 31, 2024Filed Mar 17, 2025Open the report ↗
10-QPeriod ending Sep 30, 2024Filed Nov 12, 2024Open the report ↗

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) financial health, profit and balance sheet · Scorvest